🔴 Novo Nordisk is trading 3.02% down in pre-market as no clear company-specific catalyst emerges

Novo Nordisk is trading 3.02% down at $45.75, with no fresh company-specific announcement clearly explaining the August 12 pre-market decline.

• It fell from the August 11 close of $47.17.
• Recent pressure has followed concerns about Wegovy pill sales and the CagriSema trial setback, despite raised 2026 guidance.
• Broader markets are modestly higher ahead of the August 12 CPI release, so macro sentiment does not clearly explain the isolated drop.